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Abstract 
Background Presence at the same time of HBsAg and anti-HBs antibodies (HBsAg/Ab) is an entity 
sometimes encountered in chronic hepatitis B (CHB) carriers. 
Objectives This study was designed to characterize such serological profiles and to assess the 
reliability of serological marker quantification by three commercially available assays in this setting.  
Study design Among 2578 CHB identified patients, 129 (5%) had an HBsAg/Ab profile as determined 
by Abbott Architect. After exclusion of co-infections (HIV, HCV, HDV), HBV reactivation or HBIg 
treatment, 101 samples from 62 patients were tested for HBsAg and anti-HBs quantification using 
Architect, DiaSorin Liaison-XL and Roche Modular-Cobas. Influence of genotype and HBsAg variants 
was studied in 31 samples with HBV replication. 
Results HBsAg detection was confirmed with the 3 techniques for 98% (n=99) of the samples while the 
HBsAg/Ab profile was concordant between all techniques for 65% of them. The overall correlation 
between the 3 HBsAg quantification techniques was good (r2: 0.94-0.97). The median HBsAg 
concentration was comparable for the 99 samples whatever the used technique but a bias of -0.11 
and 0.02 log IU/mL were noticed for DiaSorin and Roche compared to Abbott, respectively. Anti-HBs 
quantifications were poorly correlated between techniques with major discrepancies observed. 
Genotype and substitutions within the "a" determinant showed an impact on HBsAg quantification. 
Conclusions The double HBsAg/Ab profile is not an analytical artifact and is confirmed on all 
commercially available techniques. While such profile does not influence HBsAg quantification, 
differences of HBsAg quantification were noticed according to HBV genotype or HBsAg variant.  
 
Keywords: HBsAg quantification – HBsAg variant – Genotype – immune complexes - interference 
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Highlights 
• HBsAg and anti-HBs double positive serological profile is found in 5% of CHB 
• Concomitant detection of both markers is confirmed by 3 assays in 65% of the cases  
• HBsAg quantification is not affected by the presence of detectable anti-HBs 
• HBsAg quantification varies according to the assay, the genotype and Ag substitutions 
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Background 
HBsAg is a key marker for the diagnosis of acute or chronic HBV infection. Available qualitative or 
quantitative assays detect all circulating HBsAg containing particles, mainly infectious virions (Dane 
particles) but in a large excess non infectious/defective particles (1). While chronic infection is defined 
by the persistence of HBsAg over 6 months, HBsAg loss and appearance of anti-HBs Ab (anti-HBs) 
usually sign viral clearance. Yet, occurrence of anti-HBs is sometimes observed despite persistence of 
HBsAg and viral replication. The prevalence of this entity has been reported in less than 5 % to more 
than 25 % of CHB cases, depending on the studies (2–5). 
The molecular and immunologic mechanisms leading to this serologic profile remain unclear but could 
be due to the selection of HBV escape mutants by immune pressure (6–8). In this scenario, the 
detected circulating antibodies are directed against an HBV strain not present anymore. Indeed, 
several reports have shown an association of this pattern with an increased proportion of HBsAg 
mutants characterized by specific substitution or deletion in the preS/S gene, especially in the "a" 
determinant region. Amino acid substitutions within this epitope could modify the antigenic 
conformation of HBsAg and alter the binding of both monoclonal and polyclonal anti-HBs antibodies; 
the main consequences being the emergence of an immune escape variant and an alteration of 
HBsAg detection assay (3,4,9–13).  
Most recently, the amount of circulating HBsAg has been recognized as a potential biomarker linked to 
the liver disease stage, the risk of HCC or the chance to respond to interferon therapy (14–17). Beside 
the most widely used Architect assay (Abbott), two other CE marked assays are also available for the 
quantification of HBsAg, the Elecsys platform (Roche) and the Liaison-XL from DiaSorin. These 
assays use both mononoclonal and/or polyclonal antibodies to enhance recognition of HBsAg and 
HBsAg mutants. Several studies have convincingly demonstrated the comparable performances of 
Roche and Abbott assays (18–20). More recently, the DiaSorin assay was shown to perform 
comparably to the Architect assay in sequential serum samples from 14 HBe-negative patients (21).  
Objectives 
The aims of our study were first to document the performances of the DiaSorin assay compared to our 
routine Abbott's Architect HBsAg quantification. Secondly, the robustness of HBsAg quantification 
using the three CE marked available assays on a panel of CHB seras containing both HBsAg and anti-
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HBs was challenged. One main issue was to determine whether concomitant detection of both 
HBsAg/anti-HBs could solely be an analytical artifact linked to a specific assay. Likewise, a further 
goal was to assess the ability of these assays to quantify potential variants more prone to be selected 
in these peculiar serological profiles.  
Study design  
Patients and sera 
In the first part of the study comparing Abbott and DiaSorin on HBsAg positive samples, 227 sera 
successively tested for HBsAg quantification between September and November 2012 on Architect 
(Abbott, Rungis, France) were tested on DiaSorin Liaison-XL (Antony, France). 
One hundred and one sera corresponding to 62 CHB patients identified HBsAg/anti-HBs positive on 
Architect between January 2008 and June 2012 and stored at -20°C were selected. Exclusion criteria 
were any HIV, hepatitis C or hepatitis D coinfection, HBIg passive immunization or reactivation of past 
HBV infection. All sera were subsequently tested for HBsAg and anti-HBs on the Roche Elecsys 
system (Meylan, France) and DiaSorin Liaison-XL, according to each manufacturer's 
recommendation. The measurements were performed within 5 days on all systems.  
Among the 62 selected patients, 31 had also an HBV viral load above 100 IU/mL on the same day as 
HBsAg quantification and sequencing of the HBsAg gene could be performed on -80°C stored plasma.  
Unless specified, HBsAg quantification was reported in log10 IU/mL and anti-HBs in IU/L. The study 
general outline is presented on figure 1. 
HBsAg gene sequencing method 
HBV-DNA was purified from 500µL of plasma using Nuclisens EasyMAG (Biomérieux, Marcilly, 
France) and resuspended in 70µL of sterile water. Amplification of part of the HBsAg coding region (nt. 
186-1196, aa 100-227) was performed as previously described (4). Sequences were aligned and 
compared to selected Genbank reference sequences of known genotype using SeqScape (Applied 
Biosytems) and Mega (v5) softwares (22). For analysis purpose, HBsAg was divided into 3 regions: 
residues 100-123, 124-147 ("a" determinant) and 148-221. Substitutions were determined manually 
and with the help of two online tools (http://hbv.bioinf.mpi-inf.mpg.de/ and http://www.hiv-grade.de).  
Statistical analysis 
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Statistical analysis, were performed using Analyze-it software. Chisquare and Fischer tests were used 
for categorical variables. Mean and medians were analyzed with Mann Whitney and Kruskal tests. 
Bland-Altman analysis was used to compare methods. Significance was defined by a P value below 
0.05. 
Results 
Overall performances of Liaison-XL HBsAg quantification on 227 HBsAg positive samples 
On these 227 samples, there was a strong correlation (p<0.001) between both Abbott and DiaSorin 
systems with an r2 of 0.96 (fig. 2A) despite a mean quantification difference of -0.16 log10 IU/mL (95% 
CI: -0.19; -0.14) throughout the quantification range (fig. 2B). The results provided by the Liaison-XL 
were constantly and significantly lower than those by the Architect assay (p=0.04).  
Characteristics of patients carrying both HBsAg and anti-HBs 
Among 2578 chronic HBsAg carriers followed between 2008 and 2012, 129 (5%) patients were 
concomitantly HBsAg/anti-HBs positive and 62 (2.4%) were included in the study (fig. 1). Except from 
above mentioned inclusion criteria, available stored sample volume also restricted inclusion into the 
study. The main characteristics of the patients selected for the principal and molecular studies are 
summarized in table 1. Noteworthy, most of the samples had an anti-HBs concentration lower than 50 
IU/L (median: 24 IU/L) but 31 (30.7%) and 14 (13.9%) had values above 50 and 100 IU/L, 
respectively. No correlation was found between the concentration of HBsAg and anti-HBs (data not 
shown). The median viral load of the patients selected for S-gene sequencing was 3.6 log IU/mL; the 
best performance for sequencing being usually obtained above 1000 IU/mL.  
Qualitative analysis of the HBsAg results obtained with the three assays 
Concurrent HBsAg and anti-HBs reactivity was confirmed unequivocally with the three techniques for 
65 % of the 101 samples (table 2). The concordance between all techniques was better for HBsAg 
than for anti-HBs. Noteworthy, the median anti-HBs values obtained with Abbott for concordant (32.5 
IU/L; IQR 69.4) versus discordant (19 IU/L; IQR 21.8) results were statistically different (p=0.01).  
The HBsAg discordant samples (1 for DiaSorin and 2 for Roche) belong to the same patient who was 
followed at several visits and had persistently very low HBsAg levels: 0.07 and 0.05 IU/mL on 
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Architect (table 3). Noteworthy, a third sample with a value of 0.1 IU/mL with Abbott was correctly 
detected with Roche and DiaSorin, respectively at 0.041 UI/mL and 0.057 IU/mL. 
Quantitative analysis of HBsAg results obtained with the three assays 
All HBsAg positive data for HBsAg/anti-HBs samples were considered in the quantitative assessment 
of these assays.  
The overall correlation of all assays was satisfactory with r2 ranging from 0.93 for DiaSorin (n=100) 
and Roche (n=99) to 0.97 for Abbott and Roche assays (fig. 3). The best concordance was obtained 
between Roche and Abbott with a mean bias of 0.022 log IU/mL (95% CI: -0.024 to 0.067) in favor of 
Roche while the most divergent quantification was observed between DiaSorin and Roche (bias of 
0.130 log IU/mL in favor of Roche with 95% CI from 0.048 to 0.212). The mean bias between Architect 
and Liaison-XL was -0.113 log IU/mL; the lower values being reported by DiaSorin. A comparison of 
the biases was performed between samples concordant for the detection of both Ag and Ab on all 
techniques (n=66) to the discordant ones (n=33); no statistically significant difference was observed 
according to the discordant status. 
Quantitative analysis of the results obtained with the three assays for anti-HBs antibodies  
To limit any bias, only samples reactive (anti-HBs > 10 IU/L) with the three techniques (n=68) were 
taken into consideration for this analysis. Each technique value was compared to the obtained mean 
value on the three techniques. The best correlation was obtained with DiaSorin assay (R2 = 0.81). The 
mean differences (95% CI) to the mean for Abbott, DiaSorin and Roche were, -18.9 (-31 to -6.8); 21.2 
(8.4 to 33.9) and -2.30 (-12.1 to 7.5) IU/L, respectively (data not shown). 
Variability of HBsAg quantification according to genotypic features 
Thirty one samples could be sequenced for genotype determination and HBsAg substitution analysis 
(table 1). Ten genotype C, 8 D, 7 E, 4 B, and 1 each genotype A and F were detected. To compare 
HBsAg quantification between all techniques, the mean value obtained by the 3 techniques for each 
sample was calculated. Then, the percentage of HBsAg quantification over the mean was calculated 
for each technique and analyzed according to the genotype or the presence of substitution. 
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Sequence analyses showed that 77% (24/31 cases) of the HBsAg/anti-HBs samples harbored amino 
acid substitutions on residues 100-221. Substitutions previously described to modify HBsAg 
antigenicity were closely examined (23). Forty five percent (n=14) of the strains had such 
substitutions, with the following amino-acid changes: sT126I (n=3), sQ129G (n=1), sG130N (n=1), 
sN131H (n=1), sF134S (n=1), sC137S (n=1), sS143L (n=3), sG145R (n=2) (table 4). The most 
described sG145R substitution was detected in 2 cases (6%). All but one genotype D strains carried S 
substitution, while only 3 (30%) variants were found among the 10 genotype C strains. 
Quantification differences between the three assays according to genotype and "a" determinant 
substitutions were specifically analyzed on the three systems (figure 4 and 5). Although the size of our 
population was limited, we found a slight influence of HBV genotype on HBV quantification whatever 
the considered technique. Regarding the "a" determinant substitutions, Roche and DiaSorin 
techniques seemed to be the most affected. Noteworthy, all variants were correctly detected but 
DiaSorin tended to underestimate the variant concentration while Roche gave higher than expected 
values. 
DISCUSSION 
HBsAg concentration measurement has become a clinically relevant marker in addition to the well 
standardized panel of serological and molecular markers. As for HBV viral load, standardization of 
both the measurement unit and the techniques is mandatory to provide clinicians with comparable 
quantitative HBsAg values whatever the utilized method. Both Roche and Abbott HBsAg quantification 
techniques have been extensively studied with the conclusion that both techniques are overall very 
comparable and can be used indifferently to monitor patients (18,19,24). By contrast, the newest 
DiaSorin assay has only been studied in two small studies comparing its performance to the Abbott 
system (21,25). Our study first confirms these previous results and indicates that the Architect values 
are always 0.16 log IU/mL higher than those from the Liaison-XL. From all published studies, one may 
conclude that a patient could be followed indifferently with Abbott or Roche assay but an adjustment 
may be required if the Liaison-XL is used during follow up.  
Simultaneous detection of both HBs Ag and Ab is often puzzling in clinical situations. Indeed, although 
this peculiar profile has been described by several authors in different settings, one may wonder 
whether it corresponds to a true analytical observation (3–5,26–29). Overall, we show that the 
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qualitative agreement is 65% for the coexistence of both Ag and Ab, providing a strong argument that 
these detections are not a simple artifact. These data are comparable to the 78.6% concordance rate 
reported in a small study using only two first generation qualitative assays (30). Each of these 
techniques uses different combination of Ag and antibodies in different format and confirmation by 
three independent techniques is reassuring. According to our experience, Ag/Ab samples may 
sometimes pose problem when performing an HBsAg neutralization assay as proposed by 
manufacturers. One should stress that a thorough selection was performed in our population to not 
include clinical situations where such profiles may simply be a consequence of therapeutic 
interventions. Indeed, coexistence of both Ag and Ab markers is common during HBV reactivation 
(occurrence of HBsAg in a patient with resolved HBV infection) or administration of immunoglobulins; 
in these settings coexistence of both markers are usually only transient. In our set of samples, the 
agreement for anti-HBs detection screened by Abbott, is not as convincing as for HBsAg but reach 
86% and 71% with DiaSorin and Roche assays, respectively. In terms of correlation between anti-HBs 
measurement, the results are concordant with what observed on classical samples, anti-HBs positive 
but HBsAg negative (31). Taking into account the mean of the three techniques for anti-HBs 
determination, it should be pointed out that 15.8% (n=16) samples were above 100 IU/L, a threshold 
often considered as highly protective in exposed persons. Yet, it emphasizes the risk of considering 
someone protected against HBV infection if anti-HBs are solely looked for in a screening program; 
obviously, anti-HBs should not be used as a single screening test as it may falsely misdiagnose a 
vaccine status in a patient with an active HBV infection! (32) 
Correlations between HBsAg measurement assays were very satisfactory even in these peculiar sera 
where anti-HBs could potentially interfere with measurement (fig. 3). Astonishingly, all assays showed 
performances very similar to what observed in classical HBsAg positive samples by us and others 
(18,21,24,25,33). The concordance for HBsAg detection was also very strong and only 2 samples at 
the limit of detection by all techniques were not detected on the Elecsys. The above conclusions, 
regarding the lower values obtained on the Liaison-XL, were still valid on these Ag/Ab positive 
samples. One rationale for testing such Ag/Ab samples was the likelihood to artificially enrich our set 
with HBsAg variants (7,34). Actually, variant strains were detected in 77% (24/31) of the samples and 
45% (14/31) of the substitutions could potentially modify HBsAg antigenicity (23). Although our study 
was not primarily designed to demonstrate an influence of HBV genotype on HBsAg quantification and 
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the tested numbers are rather limited, some unexpected differences between techniques for the most 
represented genotypes, B, C, D and E were observed. This observation is currently being further 
documented in a collaborative study on more samples. Many studies have shown that "a" determinant 
variants were incorrectly detected or quantified by commercially available assays in the past (13). The 
attractive strategy of protein unfolding proposed by DiaSorin did not seem to significantly enhance the 
detection of variants and the Architect system was the less affected by the substitutions present on 
our samples (fig. 5) (25). Noteworthy, the 2 samples carrying the sG145R variant were quantified to 
the same level by all three techniques. Overall, it was not possible to identify a specific protein pattern 
that would particularly affect one technique and the most divergent results were not specifically 
observed for HBsAg variants. 
In summary, this study demonstrates the overall good performance of quantitative assays for HBsAg 
even in patients with coexisting HBs and anti-HBs. Although, the precise reasons for this entity remain 
elusive, confirmation on three techniques tend to prove that a technical artifact is not to be blamed in 
the majority of the cases. The difference observed between techniques should remind us that 
sequential monitoring should ideally be performed with a unique assay even though all techniques 
provide well correlated quantification.  
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Figure legends 
Figure 1: General outline of the study 
Figure 2: Correlation between HBsAg quantification using Abbott and DiaSorin assays (n=227) (A) and 
Bland Altman representation (B). The mean bias between both techniques was -0.162 logIU/mL. 
Figure 3: Correlation between the mean HBsAg values obtained by the three techniques (x axis) and 
values obtained by each technique (y axis) on 99 samples detected by all techniques. Abbott: closed 
circles, plain line (y = 0.9724x + 0.0361, R² = 0.9877); DiaSorin: open squares, interrupted line (y = 
1.0457x - 0.2432, R² = 0.9576); Roche: closed triangles, dotted line: (y = 1.0042x - 0.0031, R² = 
0.9801) 
Figure 4: Box plot representation of HBsAg quantification difference according to HBV genotype. 
HBsAg values expressed as IU/mL were expressed as a percentage to the mean values obtained with 
the 3 assays and grouped according to the genotype B (n=4), C (n=10), D (n=8) and E (n=7). 
Statistically significant differences according to genotype are indicated for each assay. 
Figure 5: Box plot representation of HBsAg quantification difference according to the presence of "a" 
determinant substitution. HBsAg values expressed as IU/mL were expressed as a percentage to the 
mean values obtained with the 3 assays and grouped according to the presence (Y, n=11) or absence 
(N, n=20), of "a" substitution. Statistically significant differences according to "a" substitution are 
indicated for each assay. 
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Table 1: Studied population main characteristics 
 
Parameters: median (range) Main cohort Molecular study  selected patients 
Sex ratio M/F 37/25 18/13 
Age (y) 44.9 
(22.1-79.6) 
45.2 
(22.1-72.2) 
HBsAg Abbott (IU/mL) 556 
(0.1-233 185) 
1545 
(4.7-233 185) 
Anti-HBs Ab Abbott IU/mL 24 
(11-257) 
22 
(11-115) 
 
 
Table 2: qualitative agreement between all techniques (n=101) 
 
Abbott Reactivity DiaSorin Roche DiaSorin and Roche agreement 
HBsAg 100 (99%) 99 (98%) 99 (98%) 
Anti-HBs 87 (86%) 72 (71%) 68 (67%) 
Ag/Ab 86 (85%) 70 (69%) 66 (65%) 
 
 
 
Table 3: Main results for the two HBsAg discrepant samples (samples below detection limit are 
underlined) 
 
Sample Marker Abbott DiaSorin Roche 
82 HBsAg (IU/mL) 0.07 0.032 <0.05 
 Anti-HBs (IU/L) 21 41 32 
91 HBsAg (IU/mL) 0.05 <0.030 <0.05 
 Anti-HBs (IU/L) 32 57 61 
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Table 4: Main substitutions known to influence HBsAg antigenicity detected on each strain 
 
  HBsAg residues 
NUM GENOTYPE P111 G112 S117 T118 P120 T123 T125 T126 P127 Q129 G130 T131 F134 C137 S143 G145 
90 A T         G N H     
33 B         T        
37 B                 
81 B                 
85 B                 
1 C                R 
4 C                 
5 C                 
6 C                 
29 C        I         
41 C                 
47 C                 
51 C        I         
61 C                 
130 C        I         
24 D       M  T      L  
27 D    A     T        
40 D                 
43 D         T    S    
48 D   N           S L  
101 D  R    N           
115 D                 
129 D               L  
8 E         L        
17 E                 
22 E         L       R 
32 E         L        
50 E         L        
52 E         L        
59 E         L        
15 F     Q    L        
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Figure 1 
 
  
Chronic hepatitis B carriers [2008-2012]
n=2578
HBsAg/anti-HBs profile
n=129 [5%]
Exclusion criteria:
Co-infection (HIV, HDV, HCV)
Treated with HBIg
Reactivation of past infection
n=67 [52%]
AgHBs/anti-HBs profile
n=62 [2.4%]
Samples tested for HBsAg and anti-HBs
[Abbott/Roche/DiaSorin]
n=101
Patients with HBV-VL>100 IU/mL
n=31
HBsAg gene sequencing
19 
 
Figure 2 
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Figure 3 : 
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Fig. 4  
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Fig. 5  
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